This story has been updated from a previous version.

NEW YORK, Feb 14 – Compugen said Wednesday its fourth-quarter revenues tripled to $3.3 million, compared with $1.1 million a year ago, while revenues for 2000 increased to $6.9 million from $3.2 million in 1999 due to collaborations with Pfizer and Human Genome Sciences as well as patent licensing revenue. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.